Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Taxes: 2014-2025

Historic Change in Taxes for Enanta Pharmaceuticals (ENTA) over the last 7 years, with Jun 2025 value amounting to $31.9 million.

  • Enanta Pharmaceuticals' Change in Taxes rose 7434.91% to $31.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $33.3 million, marking a year-over-year increase of 409.77%. This contributed to the annual value of $33.8 million for FY2025, which is 3295.48% up from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Change in Taxes stood at $31.9 million for Q2 2025, which was up 2,195.11% from $1.4 million recorded in Q1 2025.
  • Enanta Pharmaceuticals' Change in Taxes' 5-year high stood at $31.9 million during Q2 2025, with a 5-year trough of -$8.5 million in Q4 2021.
  • For the 3-year period, Enanta Pharmaceuticals' Change in Taxes averaged around $3.7 million, with its median value being $434,500 (2024).
  • Data for Enanta Pharmaceuticals' Change in Taxes shows a peak YoY increase of 50,970.00% (in 2023) and a maximum YoY decrease of 14,185.00% (in 2023) over the last 5 years.
  • Over the past 5 years, Enanta Pharmaceuticals' Change in Taxes (Quarterly) stood at -$8.5 million in 2021, then surged by 99.82% to -$15,000 in 2022, then skyrocketed by 4,966.67% to $730,000 in 2023, then crashed by 39.04% to $445,000 in 2024, then surged by 7,434.91% to $31.9 million in 2025.
  • Its Change in Taxes stands at $31.9 million for Q2 2025, versus $1.4 million for Q1 2025 and $445,000 for Q4 2024.